---
title: "Whitehawk Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295116309.md"
datetime: "2026-08-06T14:10:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295116309.md)
  - [en](https://longbridge.com/en/news/295116309.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295116309.md)
generator: "portal-rs"
---

# Whitehawk Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.2, beating the estimate of USD -0.3013.

EBIT: As of FY2026 Q2, the actual value is USD -18.12 M.

### Financial Results for Q2 2026 and Six Months Ended June 30, 2026

#### Cash, Cash Equivalents, and Short-Term Investments

As of June 30, 2026, Whitehawk Therapeutics, Inc. reported cash, cash equivalents, and short-term investments of $190.0 million, an increase from $145.7 million as of December 31, 2025. This balance is expected to fund operations into the second half of 2028.

#### Research and Development Expenses

For the three months ended June 30, 2026, research and development expenses were $12.9 million, a decrease from $48.8 million for the same period in 2025, which included a $38.0 million up-front license fee paid to WuXi Biologics. For the six months ended June 30, 2026, these expenses totaled $30,125 thousand, down from $57,597 thousand in the comparable period of 2025.

#### Net Loss

Whitehawk Therapeutics, Inc. reported a net loss of - $16.6 million for the three months ended June 30, 2026, an improvement from a net loss of - $52.6 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was - $38,834 thousand, compared to a net income of $20,401 thousand for the six months ended June 30, 2025.

#### Total Operating Expenses

Total operating expenses for the three months ended June 30, 2026, were $18,109 thousand, significantly lower than $54,749 thousand for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $41,631 thousand, down from $77,112 thousand in the prior year period.

#### Loss from Operations

Loss from operations was - $18,109 thousand for the three months ended June 30, 2026, compared to - $54,749 thousand for the corresponding period in 2025. For the six months ended June 30, 2026, the loss from operations was - $41,631 thousand, an improvement from - $69,967 thousand for the six months ended June 30, 2025.

#### Comprehensive Loss

Comprehensive loss for the three months ended June 30, 2026, was - $16,685 thousand, compared to - $52,607 thousand for the same period in 2025. For the six months ended June 30, 2026, comprehensive loss was - $39,017 thousand, while the company reported comprehensive income of $20,394 thousand for the six months ended June 30, 2025.

#### Other Financial Data

-   **Selling, General and Administrative Expenses**: $5,216 thousand for Q2 2026 compared to $5,940 thousand for Q2 2025; $11,506 thousand for the six months ended June 30, 2026, compared to $18,755 thousand for the six months ended June 30, 2025.
-   **Interest Income**: $1,475 thousand for Q2 2026 compared to $1,979 thousand for Q2 2025; $2,803 thousand for the six months ended June 30, 2026, compared to $2,770 thousand for the six months ended June 30, 2025.
-   **Total Assets**: $193,994 thousand as of June 30, 2026, compared to $150,830 thousand as of December 31, 2025.
-   **Total Liabilities**: $11,069 thousand as of June 30, 2026, compared to $14,519 thousand as of December 31, 2025.
-   **Total Stockholders’ Equity**: $182,925 thousand as of June 30, 2026, compared to $136,311 thousand as of December 31, 2025.

### Operational Metrics

Whitehawk Therapeutics, Inc. completed an $87.5 million private placement equity financing in May 2026.

### Outlook

Whitehawk Therapeutics, Inc. plans to initiate a Phase 1 study for HWK-206 in Q3 2026. Initial results from the HWK-007 and HWK-016 Phase 1 trials are expected in the first half of 2027. The company anticipates submitting Investigational New Drug (IND) applications for multiple new programs over the next 12-24 months.

### Related Stocks

- [WHWK.US](https://longbridge.com/en/quote/WHWK.US.md)

## Related News & Research

- [Whitehawk Therapeutics Q2 net loss narrows](https://longbridge.com/en/news/295106344.md)
- [Whitehawk Therapeutics posts corporate deck highlighting ADC platform and Phase 1 pipeline progress](https://longbridge.com/en/news/295105838.md)
- [Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload | WHWK Stock News](https://longbridge.com/en/news/287273221.md)
- [Whitehawk Therapeutics Chief Financial Officer Sold Shares Worth Over $882K](https://longbridge.com/en/news/283195291.md)
- [Whitehawk Therapeutics Chief Executive Officer Sold Shares Worth Over $899K](https://longbridge.com/en/news/282112735.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**